1. 243PGermline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. (23rd October 2018) Authors: Pohl, E; Schneeweiss, A; Hauke, J; Moebus, V; Furlanetto, J; Denkert, C; Fasching, P A; Hanusch, C; Tesch, H; Weber-Lassalle, N; Müller, V; Rhiem, K; Untch, M; Luebbe, K; Lederer, B; Jackisch, C; Nekljudova, V; Schmutzler, R K; Hahnen, E; Loibl, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Perspectives from American Society of Clinical Oncology: translational and clinical research highlights in breast and colorectal cancers. (October 2014) Authors: Fontanella, C; Aprile, G; Scartozzi, M; Lederer, B; Cascinu, S; von Minckwitz, G Journal: Future oncology Issue: Volume 10:Number 12(2014) Page Start: 1901 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto. (18th October 2018) Authors: Loibl, S; Weber, K E; Timms, K M; Elkin, E P; Hahnen, E; Fasching, P A; Lederer, B; Denkert, C; Schneeweiss, A; Braun, S; Salat, C T; Rezai, M; Blohmer, J U; Zahm, D M; Jackisch, C; Gerber, B; Klare, P; Kümmel, S; Schem, C; Paepke, S Journal: Annals of oncology Issue: Volume 29:Number 12(2018) Page Start: 2341 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗